NDC Package 70859-041-01 Point Of Care Lm Dep 2

View Billable Units, 11-Digit Format, RxNorm

Package Information
Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:

70859-041-01

Package Description:

1 KIT in 1 CARTON * 1 VIAL, SINGLE-DOSE in 1 PACKAGE (0009-3073-01) / 1 mL in 1 VIAL, SINGLE-DOSE * 5 mL in 1 POUCH * 10 mL in 1 PACKET * 5 mL in 1 SYRINGE

Product Code:

70859-041

Proprietary Name:

Point Of Care Lm Dep 2

Usage Information:

Bupivacaine hydrochloride injection, USP is indicated for the production of local or regional anesthesia or analgesia for surgery, oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (See WARNINGS.) Experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of bupivacaine hydrochloride injection, USP in these patients. Bupivacaine hydrochloride injection, USP is not recommended for intravenous regional anesthesia (Bier Block). See WARNINGS. The routes of administration and indicated bupivacaine hydrochloride injection, USP concentrations are: local infiltration 0.25%peripheral nerve block 0.25% and 0.5%retrobulbar block 0.75%sympathetic block 0.25%lumbar epidural 0.25%, 0.5%, and 0.75% (0.75% not for obstetrical anesthesia) caudal 0.25% and 0.5%epidural test dose (see PRECAUTIONS) (See DOSAGE AND ADMINISTRATION for additional information.) Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of bupivacaine hydrochloride injection, USP. A. For Intramuscular AdministrationWhen oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows:Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions.Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis.Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.Neoplastic Diseases: For palliative management of: leukemias and lymphomas.Nervous System: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.Ophthalmic Diseases: Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids.Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus.Respiratory Diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.B. For Intra-articular Or Soft Tissue Administration(See WARNINGS)DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.C. For Intralesional AdministrationDEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum.DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).

11-Digit NDC Billing Format:

70859004101

Billing Unit:

EA - Billing unit of "each" is used when the product is dispensed in discreet units.

NDC to RxNorm Crosswalk:

RxCUI: 1737566 - lidocaine HCl 1 % in 5 ML Injection

RxCUI: 1737566 - 5 ML lidocaine hydrochloride 10 MG/ML Injection

RxCUI: 1737566 - lidocaine HCl 1 % per 5 ML Injection

RxCUI: 1737566 - lidocaine HCl 50 MG per 5 ML Injection

RxCUI: 1743779 - methylPREDNISolone acetate 40 MG in 1 ML Injection

Labeler Name:

Nucare Pharmaceuticals,inc.

Sample Package:

Start Marketing Date:

11-05-2013

Listing Expiration Date:

12-31-2022

Exclude Flag:

Code Structure:

70859 - Nucare Pharmaceuticals,inc.
- 70859-041 - Point Of Care Lm Dep 2
  - 70859-041-01 - 1 KIT in 1 CARTON * 1 VIAL, SINGLE-DOSE in 1 PACKAGE (0009-3073-01) / 1 mL in 1 VIAL, SINGLE-DOSE * 5 mL in 1 POUCH * 10 mL in 1 PACKET * 5 mL in 1 SYRINGE

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

Frequently Asked Questions

What is NDC 70859-041-01?

The NDC Packaged Code 70859-041-01 is assigned to a package of 1 kit in 1 carton * 1 vial, single-dose in 1 package (0009-3073-01) / 1 ml in 1 vial, single-dose * 5 ml in 1 pouch * 10 ml in 1 packet * 5 ml in 1 syringe of Point Of Care Lm Dep 2, labeled by Nucare Pharmaceuticals,inc.. The product's dosage form is and is administered via form.

Is NDC 70859-041 included in the NDC Directory?

No, Point Of Care Lm Dep 2 with product code 70859-041 is excluded from the NDC Directory because it's listing has been INACTIVATED by FDA. The product was first marketed by Nucare Pharmaceuticals,inc. on November 05, 2013 and its listing in the NDC Directory is set to expire on December 31, 2022 if the product is not updated or renewed by the manufacturer.

What is the NDC billing unit for package 70859-041-01?

The contents of this package are billed per "each", products billed on a per each basis are usually products dispensed in discreet units.

What is the 11-digit format for NDC 70859-041-01?

The 11-digit format is 70859004101. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

10-Digit Format	10-Digit Original Code	11-Digit Format	11-Digit Code
5-3-2	70859-041-01	5-4-2	70859-0041-01

Table of Contents